质谱法相对定量II型先天性糖基化障碍患者血浆N-聚糖
该研究建立了一种基于同位素衍生化和质谱的相对定量方法,用于分析II型先天性糖基化障碍(CDG-II)患者血浆N-聚糖。方法将对照血浆混合后用氘代碘甲烷衍生化作为内标,患者样本用碘甲烷衍生化,经MALDI MS和LC-MS/MS分析。该方法为CDG-II的质谱诊断提供了可行替代方案,可能有助于发现新的诊断性聚糖。
要点
- 建立同位素衍生化质谱法相对定量血浆N-聚糖,可降低次要成分变异性。
- 方法对低浓度但生物学相关结构敏感,可能辅助发现新诊断聚糖。
核心结论
- 该质谱相对定量方法为CDG-II诊断提供了可行替代方案,并可能有助于发现其他亚型的新诊断性聚糖。
研究设计与样本
- 方法学研究:对照血浆混合后经氘代碘甲烷衍生化作为内标,患者样本经碘甲烷衍生化,行MALDI MS和LC-MS/MS分析。
主要发现
- 4例详细分析病例包括2例ATP6V0A2-CDG同胞和2例MAN1B1-CDG患者,其中1例携带既往未描述的p.Gly536Val突变。
临床怎么用
- 该方法可用于CDG-II的质谱诊断,尤其对低浓度但生物学相关的聚糖结构具有敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type II Congenital Disorders of Glycosylation (CDG-II) are a group of diseases with challenging diagnostics characterized by defects in the processing of glycans in the Golgi apparatus. Mass Spectrometry (MS) has been a valuable tool in the definition of CDG-II subtypes. While some CDG-II subtypes are associated with specific N-glycan structures, others only produce changes in relative levels, reinforcing the demand for quantification methods. METHODS: Plasma samples from control individuals were pooled, derivatized with deuterated iodomethane (I-CD3), and used as internal standards for controls and patients whose glycans were derivatized with iodomethane (I-CH3), followed by MALDI MS, LC-MS and -MS/MS analyses. RESULTS: Total N-glycans from fifteen CDG-II patients were evaluated, and 4 cases with molecular diagnosis were considered in detail: 2ATP6V0A2-CDG siblings, and 2 MAN1B1-CDG patients, one of them carrying a previously undescribed p.Gly536Val mutation. CONCLUSIONS: Our methodology offers a feasible alternative to the current methods for CDG-II diagnosis by MS, which quantify glycan structures as fractions of the total summed signal across a mass spectrum, a strategy that lowers the variability of minor components. Moreover, given its sensitivity for less concentrated yet biologically relevant structures, it might assist the uncovering of novel diagnostic glycans in other CDG-II subtypes.
引用
- Barbosa EA, Fontes NDC, Santos SCL, et al. Relative quantification of plasma N-glycans in type II congenital disorder of glycosylation patients by mass spectrometry. Clin Chim Acta. 2019. PMID: 30776362. doi:10.1016/j.cca.2019.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。